From Conventional to Unusual Enzyme Inhibitor Scaffolds: The Quest for Target Specificity
Author:
- 15 February 2011
- journal article
- review article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 50 (11) , 2442-2448
Abstract
The tremendous challenge presented by the specific molecular recognition of single biomacromolecular targets within complex biological systems demands novel and creative design strategies. This Minireview discusses some conventional and unusual approaches for the design of target‐selective enzyme inhibitors with a focus on the underlying chemical scaffolds. These include complicated natural‐product‐like organic molecules, stable octahedral metal complexes, fullerenes, carboranes, polymetallic clusters, and even polymers. Thus the whole repertoire of organic, inorganic, and macromolecular chemistry can be applied to tackle the problem of target‐specific enzyme inhibition.Keywords
This publication has 45 references indexed in Scilit:
- Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profilesProceedings of the National Academy of Sciences, 2010
- Natural Products as Chemical ProbesACS Chemical Biology, 2010
- (Arene)Ru(II) complexes of epidermal growth factor receptor inhibiting tyrphostins with enhanced selectivity and cytotoxicity in cancer cellsEuropean Journal of Medicinal Chemistry, 2010
- On the potential of natural products in the discovery of pharma leads: A case for reassessmentNatural Product Reports, 2010
- A crowdsourcing evaluation of the NIH chemical probesNature Chemical Biology, 2009
- New Protein Kinase CK2 Inhibitors: Jumping out of the Catalytic BoxChemistry & Biology, 2009
- Structural and biological investigation of ferrocene-substituted 3-methylidene-1,3-dihydro-2H-indol-2-onesDalton Transactions, 2008
- Targeting Large Kinase Active Site with Rigid, Bulky Octahedral Ruthenium ComplexesJournal of the American Chemical Society, 2008
- A systematic interaction map of validated kinase inhibitors with Ser/Thr kinasesProceedings of the National Academy of Sciences, 2007
- Finishing the euchromatic sequence of the human genomeNature, 2004